AMYLOID LIGHT-CHAIN AMYLOIDOSIS
Clinical trials for AMYLOID LIGHT-CHAIN AMYLOIDOSIS explained in plain language.
Never miss a new study
Get alerted when new AMYLOID LIGHT-CHAIN AMYLOIDOSIS trials appear
Sign up with your email to follow new studies for AMYLOID LIGHT-CHAIN AMYLOIDOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise in destroying amyloidosis cells
Disease control Not yet recruitingThis study tests an experimental drug called elranatamab in people newly diagnosed with AL amyloidosis who have not yet had treatment. The drug helps the body's immune cells find and destroy the abnormal cells causing the disease. Researchers want to see if it can produce deep re…
Matched conditions: AMYLOID LIGHT-CHAIN AMYLOIDOSIS
Phase: PHASE2 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for rare amyloidosis: targeted drug combo enters trial
Disease control Not yet recruitingThis Phase 2 trial tests a new drug, belantamab mafodotin, combined with standard chemotherapy in 60 adults newly diagnosed with AL amyloidosis, a rare disease where abnormal proteins damage organs. The goal is to see if the combination improves blood and organ responses. The stu…
Matched conditions: AMYLOID LIGHT-CHAIN AMYLOIDOSIS
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC